Ixekizumab showed superiority versus guselkumab in the treatment of moderate to severe plaque psoriasis.
Data presented at the fifth Annual Maui Derm NP+PA Fall meeting has revealed that ixekizumanb (Taltz, Eli Lilly and Company) showed superiority versus guselkumab (Tremfya, Janssen) in patients with moderate to severe plaque psoriasis.
The results are based on the phase 4 IXORA-R study, the first head-to-head study between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint.
A total of 1027 patients with moderate to severe plaque psoriasis were enrolled in the study to evaluate the efficacy and safety of ixekizumanb compared with guselkumab. Participants were randomized to receive ixekizumanb or guselkumab at the approved dose for a total of 24 weeks, with the primary analysis conducted at 12 weeks.
Ixekizumanb met the primary endpoint of superiority versus guselkumab in the proportion of patients with moderate to severe plaque psoriasis achieving complete skin clearance as measured by PASI 100 at week 12, as well as key secondary endpoints.
In IXORA-R, the safety profiles of ixekizumanb and guselkumab were consistent with those previously reported for both treatments.
The study is ongoing through week 24. The results on the remaining key secondary endpoint of proportion of patients achieving PASI 100 at 24 weeks are expected to be released in 2020.
1. New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis [press release]. Published October 3, 2019. https://www.biospace.com/article/releases/new-head-to-head-data-show-taltz-ixekizumab-superiority-versus-tremfya-guselkumab-in-people-with-moderate-to-severe-plaque-psoriasis/. Accessed October 3, 2019.